Neurotoxicity of Drugs of Abuse
- 1st Edition, Volume 8 - September 15, 2022
- Imprint: Academic Press
- Editors: Lucio G. Costa, Michael Aschner, William Slikker Jr.
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 1 5 8 5 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 1 5 8 6 - 1
Neurotoxicity of Drugs of Abuse, Volume Eight provides carefully crafted reviews on the disruptive impact of drugs of abuse on the central nervous system. The neurotoxi… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNeurotoxicity of Drugs of Abuse, Volume Eight provides carefully crafted reviews on the disruptive impact of drugs of abuse on the central nervous system. The neurotoxicity potential of several agents including marijuana, fentanyl, and ketamine are carefully reviewed, and their short-term and chronic effects are categorized. Pharmacokinetic profiles as well as mechanisms of action for these and other drugs of abuse such as alcohol and nicotine are also evaluated. The implications of short and long-term abuse for agents such as PCP are also characterized. The reader will come away with a fuller understanding of the adverse effects of drugs of abuse on the nervous system.
- Describes in detail the characteristics of drugs of abuse that produce neurotoxicity
- Summarizes both the short and long-term adverse effects of drugs of abuse on the nervous system
- Describes potential mechanisms of action of centrally acting drugs of abuse
Basic researchers, clinicians, epidemiologists, regulators, drug developers, chemists
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- References
- Chapter One: Cannabinoids
- Abstract
- 1: Introduction
- 2: The endocannabinoid system (ECS)
- 3: Endocannabinoid system influence on the generation of neural cells
- 4: Biological basis for potential adverse effects
- 5: Conclusions
- References
- Chapter Two: Converging mechanisms in ethanol neurotoxicity
- Abstract
- 1: Introduction
- 2: Ethanol metabolism
- 3: Neurotransmission and intracellular pathways
- 4: Oxidative stress
- 5: Animal models of ethanol-induced neurotoxicity
- 6: Conclusions and future considerations
- Acknowledgments
- References
- Chapter Three: Neurotoxicology of nicotine and tobacco
- Abstract
- 1: Introduction
- 2: Prenatal and neonatal development
- 3: Adolescence
- 4: Adulthood
- 5: Aging
- 6: Future directions
- 7: Summary and conclusions
- Acknowledgment
- References
- Chapter Four: The neurotoxic potential of opioids including fentanyl and fentanyl analogs
- Abstract
- 1: Introduction
- 2: Neurotoxicology of fentanyl and related compounds
- 3: Conclusions
- References
- Chapter Five: Phencyclidine (PCP)-induced neurotoxicity and behavioral deficits
- Abstract
- 1: Introduction
- 2: Experimental evidence for PCP-induced neurotoxicity
- 3: Potential basic mechanisms underlying PCP-induced neurotoxicity
- 4: Prevention/improvement of PCP-induced neurotoxicity
- 5: Summary
- Acknowledgments
- References
- Further reading
- Chapter Six: The mysterious beauty of ketamine: Benefits and risks
- Abstract
- 1: Introduction
- 2: Between PCP and ketamine
- 3: Ketamine and apoptosis
- 4: Ketamine-induced psychosis
- 5: Ketamine and schizophrenic symptoms
- 6: Ketamine and cognitive functioning
- 7: Conclusion
- References
- Edition: 1
- Volume: 8
- Published: September 15, 2022
- No. of pages (Hardback): 194
- No. of pages (eBook): 194
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780323915854
- eBook ISBN: 9780323915861
LC
Lucio G. Costa
Dr. Lucio G. Costa is Professor of Toxicology at the University of Washington in Seattle, and of Pharmacology/Toxicology at the University of Parma Medical School. He received a doctorate in Pharmacology from the University of Milano in 1977, and was a postdoctoral fellow at the University of Texas at Houston. He is a member of several national and international professional organizations, a Fellow of the Academy of Toxicological Sciences, and a European Certified Toxicologist. He received various award for his scientific accomplishments, including the Achievement Award from the Society of Toxicology. He serves in various editorial capacities for several toxicology journals, and is an active manuscript and grant reviewer. Dr. Costa has been the member of dozens of panels and committees at the national and international level dealing with toxicology and risk assessment issues. He has chaired and/or organized symposia at scientific meetings in the United States and internationally. He has been teaching classes in the area of toxicology, neurotoxicology and pharmacology to graduate and medical students for 30 years. He keeps an active research program in the area of neurotoxicology.
Affiliations and expertise
Professor of Toxicology, University of Washington, Seattle, WA, USAMA
Michael Aschner
Dr. Aschner serves as the Harold and Muriel Block Chair in Molecular Pharmacology at Albert Einstein College of Medicine. He served on numerous toxicology panels (Institute of Medicine, US Environmental Protection Agency, Center for Disease Control), and is a member of the Neurotoxicology and Alcohol study section (NIH). Research in our lab focuses on the following topics: (1) Modulation of C. elegans genes (aat, skn-1, daf-16) that are homologous to mammalian regulators of MeHg uptake and cellular resistance will modify dopaminergic neurodegeneration in response to MeHg exposure. (2) Under conditions of MeHg-induced oxidative stress, Nrf2 (a master regulator of antioxidant responses) coordinates the upregulation of cytoprotective genes that combat MeHg-induced oxidative injury, and that genetic and biochemical changes that negatively impact upon Nrf2 function increase MeHg’s neurotoxicity. (3) PARK2, a strong PD genetic risk factor, alters neuronal vulnerability to modifiers of cellular Mn status, particularly at the level of mitochondrial dysfunction and oxidative stress. Our studies are designed to (1) shed novel mechanistic insight into metal-induced neurodegeneration; (2) identify targets for genetic or pharmacologic modulation of neurodegenerative disorders; (3) increase knowledge of the pathway involved in oxidative stress; (4) develop improved research models for human disease using knowledge of environmental sciences.
Affiliations and expertise
Professor, Department of Molecular Pharmacology, Albert Einstein College of Medicine, NY, USAWS
William Slikker Jr.
Dr. William Slikker, Jr. was the director of FDA’s National Center for Toxicological Research (NCTR) before his retirement. He received his Ph.D. in pharmacology and toxicology from the University of California at Davis. Dr. Slikker holds adjunct professorships in the Department of Pediatrics, as well as the Department of Pharmacology and Toxicology at the University of Arkansas for Medical Sciences. He has held committee chairmanships or elected offices in several scientific societies including the Teratology Society (serving as president) and the American Society for Pharmacology and Experimental Therapeutics (chair, Developmental Pharmacology Section and member, Program Committee). Dr. Slikker is also the co-founder and past president of the MidSouth Computational Biology and Bioinformatics Society. He is currently associate editor for NeuroToxicology and associate editor for the “Environmental Health” section of Experimental Biology and Medicine. He is the past president of The Academy of Toxicological Sciences and the Society of Toxicology. He is a recipient of the 2014 George H. Scott Memorial Award from The Toxicology Forum and was invited to present the Warkany Lecture at the 2015 annual meeting of the Teratology Society. In early 2019, the Academy of Toxicological Sciences selected Dr. Slikker to receive the prestigious Mildred S. Christian Career Achievement Award. The Society for Birth Defects Research and Prevention selected Dr. Slikker to be the recipient of the 2022 Edward W. Carney Distinguished Service Award.
Dr. Slikker has authored or co-authored over 380 publications in the areas of transplancentalpharmacokinetics, developmental neurotoxicology, neuroprotection, systems biology, and risk assessment. Dr. Slikker’s recent research has highlighted the concern for thousands of infants and toddlers who undergo longer-duration general anesthesia. He has performed research with his team and published over 25 peer-reviewed papers outlining the issue of brain-cell death and cognitive-function deficits in animal models that may result from several hours of anesthesia at a critical time of development. He has also, with the use of in vitro and in vivo techniques in rodents and nonhuman primates, defined possible mechanisms of toxicity and protective pathways to prevent the detrimental effects of general anesthesia. Through these and related scientific contributions, he has identified and characterized a host of minimally invasive biomarkers of neurotoxicity including the use of preclinical imaging (MRI, MicroPET/CT), genomic and lipidomic analysis, and modeling approaches to characterize and quantify adult and developmental neurotoxicity. He has also served on several national/international advisory panels for ILSI, HESI, CIIT, EPA, NIEHS, NAS, NIH and WHO.
Affiliations and expertise
National Center for Toxicological Research, Jefferson, US FDA, AR, USARead Neurotoxicity of Drugs of Abuse on ScienceDirect